FutureMe Co., Ltd.
University-originated venture FuturedMe, a Japanese decomposition drug discovery platform CANDDY, selected for NEDO’s “Deep Tech Startup Support Project”
……
FuturedMe Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Representative: Etsuko Miyamoto, hereinafter referred to as FutureMe), a
university-based venture company, has recently announced that it has received deep tech startup support from the New Energy and Industrial Technology Development Organization (hereinafter referred to as NEDO). In the STS phase, we applied for the second round of public
recruitment for the “CANDDY Disease-Specific Degradative Drug Discovery Support Platform” project with our partner VC (KSP Corporation). We would like to inform you that your proposal has been adopted.
FuturedMe was established based on the world’s first unique drug discovery technology “CANDDY(TM)” invented by the founder (currently CEO) from Japan. FuturedMe will bring about a game change in the world of drug discovery and deliver “Future Drug CANDDY(TM) (drug=degrader)” to each person (Me). FuturedMe’s mission is “No patients without medicine.”
[Image 1
■What is NEDO’s “Deep Tech Startup Support Project”? Long-term research and development and large-scale funding are required to establish technology, commercialize it, and implement it in
society.Although the risks are high, the economic and social issues must be addressed by the country and the world as a whole. For “Deep Tech Startups” that are engaged in research and development of innovative technologies that are thought to contribute to solving problems, there are three phases ([1] STS phase (practical research and development (first half)) until commercialization. ), [2] PCA phase (practical research and development (late stage)), and [3] DMP phase (mass production demonstration)). After implementing the project in each phase, if it is approved in the stage gate examination, it will be possible to continue implementing the project by proceeding to the next phase.
Reference URL: https://www.nedo.go.jp/activities/ZZJP_100250.html ■Selected subsidized projects
[Image 2
With this NEDO-DTSU selection, FuturedMe will differentiate itself by leveraging the characteristics of CANDDY, the world’s first original next-generation decomposition drug discovery technology developed in Japan, and will realize a platform that expands indications and avoids side effects. .
In the STS phase, if we can pass the stage gate examination by establishing a system to receive advice from clients early on, we will develop a commercialization prototype POC for the disease-specific target degradation CANDDY platform and partner with clients in the next PCA phase. Aim for the ring. After the completion of PCA, we plan to further expand and strengthen our network centered on the CANDDY platform and conduct joint research on drug discovery and development for various diseases and targets.
Business goals: 1) disease-specific targeted degradation, 2) naturally denatured protein degradation, and 3) initial prototype POC. By achieving these, we will provide new value as a next-generation degradation drug discovery technology. NEDO-DTSU selection results publication page URL: https://www.nedo.go.jp/koubo/CA3_100419.html ■CANDDY technology
[Image 4
■Comment from partner VC KSP Co., Ltd.
[Image 6
CANDDY technology is my second invention, conceived at the Institute of Medical Science, University of Tokyo, and researched and developed at Tokyo University of Science.The first invention led to the launch of multiple ventures, but even with the same technology, it is not successful. I have experienced that there are ventures and
non-ventures. That has been a mystery for many years. By meeting our partner VC, KSP (the Kubota team, former president of Bepeti Dream), I realized the importance of business models and the necessity for everyone to be on the same page towards a single goal. At NEDO-DTSU, we are confident that by aligning our vectors with our partner VC and working together towards our goals, our dream of expanding our business around the world, armed with original technology from Japan, will come true in the near future. Masu.
In the NEDO-DTSU project, our company will firmly develop its technological capabilities, build a platform that takes advantage of the characteristics of the technology, and aim for a world in which no patient will give up on treatment due to a lack of drugs in future genomic medicine.
■About recruiting advisors for pharmaceutical companies
FuturedMe needs advice from pharmaceutical companies as we move forward with the NEDO-DTSU STS phase. If you are interested in participating as a NEDO expert (advisor) or interested in future joint research or partnership, please contact admin@futuredme.com. ■Recruiting Human Resources In order to focus more on research and development in the future, FuturedMe is recruiting medicinal chemistry researchers (synthesis specialists, or those who can perform everything from synthesis to cell and animal evaluation). If you are interested, please contact admin@futuredme.com.
■About FuturedMe Co., Ltd. [Company Profile] Company name: FuturedMe Co., Ltd. Head office location: 2-3-11 Nihonbashi Honmachi, Chuo-ku, Tokyo Representative Director and CEO: Etsuko Miyamoto Established: June 2018 Business details: Proprietary drug discovery technology “CANDDY” A university-based startup that conducts research and development. “CANDDY” is a technology that utilizes protein
degradation phenomena in living organisms to induce the degradation of target proteins that cause disease. It is characterized by not depending on the ubiquitination process. Their mission is “No patients without medicine.”
[Image 8
Background: 2018: Established FutureMe Co., Ltd. 2018: Obtained exclusive license for CANDDY patent from Tokyo University of Science 2019: Obtained “S” post evaluation for JST START “Miyamoto CANDDY Project” 2020: Selected for Forbes Japan 2020 TOP 200 2021: Received the Cabinet Office “Women’s Challenge Award” 2021: Basic patent for CANDDY technology registered in Japan, the United States, etc. 2022: J-TECH STARTUP 2022 certified 2022: Adopted by the Himawari Venture Fund 2023: Small and Medium Enterprise Agency FASTER No. 8th term support selection 2023: NEDO-DTSU 2nd public recruitment selection website: https://futuredme.com/jp/#secNews